These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 1375094

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
    Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Johnston PB, Hogan WJ, Gertz MA.
    Am J Hematol; 2010 Jun; 85(6):409-13. PubMed ID: 20513117
    [Abstract] [Full Text] [Related]

  • 25. Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.
    Scher HI, Curley T, Yeh S, Tong W, O'Moore PV, Larson S.
    Adv Exp Med Biol; 1992 Jun; 324():115-29. PubMed ID: 1283494
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.
    Higano CS, Quick DP, Bushnell D, Sartor O.
    Clin Genitourin Cancer; 2008 Mar; 6(1):40-5. PubMed ID: 18501082
    [Abstract] [Full Text] [Related]

  • 28. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
    Bal C, Arora G, Kumar P, Damle N, Das T, Chakraborty S, Banerjee S, Venkatesh M, Zaknun JJ, Pillai MR.
    Curr Radiopharm; 2016 Mar; 9(1):71-84. PubMed ID: 25771371
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.
    Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, Ketring AR.
    J Nucl Med; 1989 Nov; 30(11):1814-8. PubMed ID: 2478681
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Samarium-153 lexidronam for painful bone metastases.
    Med Lett Drugs Ther; 1997 Aug 29; 39(1008):83-4. PubMed ID: 9286284
    [No Abstract] [Full Text] [Related]

  • 35. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W, Kampen WU, Kampen AM, Henze E.
    J Nucl Med; 2001 Feb 29; 42(2):230-6. PubMed ID: 11216521
    [Abstract] [Full Text] [Related]

  • 36. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate].
    Lovera C, Massardo T, Galleguillos MC, González P, Comparini B, Yáñez M, Fodor M, Gil MC, Araya G, Tomicic M.
    Rev Med Chil; 1998 Aug 29; 126(8):963-71. PubMed ID: 9830748
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.
    Sapienza MT, Ono CR, Guimarães MI, Watanabe T, Costa PA, Buchpiguel CA.
    Rev Hosp Clin Fac Med Sao Paulo; 2004 Dec 29; 59(6):321-8. PubMed ID: 15654484
    [Abstract] [Full Text] [Related]

  • 39. Samarium for osteoblastic bone metastases and osteosarcoma.
    Anderson P.
    Expert Opin Pharmacother; 2006 Aug 29; 7(11):1475-86. PubMed ID: 16859431
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.